Novavax, Inc. reported an insider ownership change for Richard J. Rodgers involving the company’s common stock, with the reported transaction date of June 18, 2026. The filing was signed on June 23, 2026, by Mark J. Casey as attorney-in-fact for Rodgers. The reported action relates to equity compensation granted under Novavax’s Amended and Restated 2015 Stock Incentive Plan, as amended. The filing describes a new stock option grant dated June 18, 2026, under which 100% of the option shares will vest on the first anniversary of the grant date, provided Rodgers continues serving on Novavax’s Board of Directors through the vesting date. The filing also reports a restricted stock unit grant made on June 18, 2026. Each RSU represents a contingent right to receive one share of Novavax common stock. Like the option award, 100% of the RSUs subject to the 2026 grant are scheduled to vest on the first anniversary of the grant date, subject to continued Board service. In addition, the filing notes that RSUs granted on June 20, 2025 vested on the first anniversary of that grant date, also conditioned on continued Board service through the vesting date. This indicates that the ownership change includes both newly granted director equity awards and the vesting of a prior RSU award. The provided document text does not disclose the specific number of shares or RSUs, the option exercise price, transaction codes, or Rodgers’ beneficial ownership after the reported transactions. Based on the explanatory notes, the reported activity appears to be director compensation-related equity grants and vesting, rather than an open-market purchase or sale.